MBAL Sveta Karidad EAD
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The First Department of Internal Medicine at MBAL Sveta Karidad EAD conducts studies aimed at reducing cardiovascular risk and improving outcomes after heart events. Trials explore the use of innovative anti‑inflammatory agents such as ziltivekimab to lower major adverse cardiovascular events, evaluate rapid self‑administered therapy for acute myocardial infarction, and assess new combinations for managing heart failure with preserved ejection fraction.
- Acute myocardial infarction (AMI)
- Heart failure with preserved or mildly reduced ejection fraction
- Atherosclerotic cardiovascular disease
- Chronic kidney disease and hypertension
- Type 2 diabetes with cardiovascular disease
These investigations reflect the site’s commitment to advancing heart health for patients throughout Plovdiv and beyond.
Digestive System Diseases
Research in the digestive system focuses on liver and intestinal disorders. The site evaluates novel therapies for non‑alcoholic steatohepatitis and related metabolic liver disease, compares biosimilars for ulcerative colitis, and tests new acid‑suppression drugs for erosive esophagitis caused by GERD.
- Non‑alcoholic steatohepatitis (NASH)
- Metabolic dysfunction‑associated steatotic liver disease (MASLD)
- Moderate to severe active ulcerative colitis
- Moderately to severely active Crohn's disease
- Erosive esophagitis due to gastroesophageal reflux disease
The program supports patients with chronic liver and bowel conditions in the region, offering access to cutting‑edge treatments.
Nutritional and Metabolic Diseases
Metabolic and nutritional studies target obesity and lipid abnormalities. Ongoing work includes agents that reduce body weight in overweight individuals, treatments to lower severe hypertriglyceridemia, and strategies that address the underlying metabolic dysfunction linked to type 2 diabetes and cardiovascular disease.
- Obesity
- Severe hypertriglyceridemia
- Metabolic dysfunction‑associated steatohepatitis
- Type 2 diabetes with cardiovascular risk
- Hypertriglyceridemia
These trials aim to provide safer, more effective options for managing metabolic health in the Bulgarian population.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 29 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1AstraZeneca AB3active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB5trials
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MBAL Sveta Karidad EAD
lock Showing 1 of 28 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 29 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 4 | Unknown | 2024-06-05 | 2026-04-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.